
    
      Phase 1 study to determine the feasibility of the combination of the proteasome inhibitor
      bortezomib (PS-341, Velcade) with trastuzumab (Herceptin) given either weekly or 3-weekly.

      Additionally, hints about efficacy of the combination will be looked upon.
    
  